A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis

作者：Cho Jae Min; Jang Hye Won; Cheon Hwanju; Jeong Yeon Taek; Kim Do Hoon; Lim Yu Mi; Choi Song hyen; Yang Eun kyoung; Shin Chang Yell; Son Moon Ho; Kim Soon Hoe; Kim Heung Jae; Lee Myung Shik^*

来源：Diabetes Research and Clinical Practice, 2011, 91(1): 72-79.

DOI：10.1016/j.diabres.2010.10.012

• Dipeptidyl peptidase IV
• Glucagon-like peptide 1
• beta-Cell
• Diabetes

We studied the effect of a novel dipeptidyl peptidase IV (DPP IV) inhibitor, DA-1229, on blood glucose profile and pancreatic beta-cell mass in established diabetes after streptozotocin (STZ) treatment. Mice that developed diabetes after administration of STZ 100 mg/kg were treated with DA-1229 for 13 weeks. DA-1229 significantly reduced plasma DPP IV activity, and enhanced glucagon-like peptide 1 (GLP-1) levels. In STZ-treated mice fed DA-1229 (STZ-DA), blood glucose levels were significantly lower than those in diabetic mice fed normal chow (STZ-NC). Basal and glucose-stimulated insulin secretion and glucose tolerance assessed by intraperitoneal glucose tolerance test were significantly improved by DA-1229 administration. Volume density of beta-cell was significantly increased in STZ-DA mice compared to STZ-NC mice, suggesting that DA-1229-mediated amelioration of established diabetes was due to beneficial effect of DA-1229 on beta-cell mass. The number of replicating beta-cells and that of scattered small beta-cell unit representing beta-cell neogenesis were significantly increased in STZ-DA mice compared to STZ-NC mice, explaining increased beta-cell mass by DA-1229. The expression of PDX-1, a downstream mediator of GLP-1 action, was increased in islets of STZ-DA mice compared to STZ-NC mice. These results suggest a therapeutic potential of DA-1229 in diabetes, particularly that associated with decreased beta-cell mass.

• 出版日期2011-1